Study details
Enrolling now
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
Baylor College of Medicine
NCT IDNCT01853631ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
64
Study length
about 22 years
Ages
≤75
Locations
2 sites in TX
What this study is about
This trial is testing a new treatment for people with advanced B-cell Non-Hodgkin Lymphoma, acute lymphocytic leukemia, or chronic lymphocytic leukemia. The treatment involves modifying T cells to target cancer cells more effectively. This is a Phase 1 trial.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Dose Escalation Phase:CD19.CAR/28 and CD19.CAR/28137 T cells
- 2.Take Expansion Phase: CD19.CAR/28 and CD19.CAR/28137 T cells
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Injection / IVInjection / IV
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug routes
injection, intravenous
Endpoints
Primary: Number of patients with dose limiting toxicity (DLT)
Body systems
Oncology